参麦注射液联用瑞舒伐他汀钙治疗急性缺血性脑卒中临床观察

Clinical Observation on Shenmai Injection Combined with Rosuvastatin Calcium for Acute Ischemic Stroke

目的:观察参麦注射液联用瑞舒伐他汀钙对急性缺血性脑卒中(AIS)患者氧化应激及脂质过氧化的影响。方法:将80例AIS患者按照随机数字表法分为2组各40例。2组患者均给予AIS常规治疗,对照组在此基础上加用瑞舒伐他汀钙治疗,研究组加用瑞舒伐他汀钙及参麦注射液治疗,2组均治疗至少3周。于治疗前后对患者进行美国国立卫生研究院卒中量表(NIHSS)评分、氧化低密度脂蛋白(Ox-LDL)、超氧化物歧化酶(SOD)、血清甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、脂质过氧化物8-异前列腺素F2α(8-iso-PGF2α)浓度的测定,并且评价2组临床疗效及安全性。结果:临床疗效总有效率研究组高于对照组,但差异无统计学意义(P> 0.05)。治疗后,2组NIHSS评分均明显降低,且研究组评分低于对照组,差异均有统计学意义(P <0.05,P <0.01)。2组TG、TC及LDL-C均明显下降,而HDL-C明显升高,差异均有统计学意义(P <0.01),研究组各指标改变明显于对照组,差异均有统计学意义(P <0.05,P <0.01)。治疗后,对照组患者Ox-LDL升高,SOD及8-iso-PGF2α下降,其中8-iso-PGF2α浓度前后比较,差异有统计学意义(P <0.01);研究组患者OxLDL及8-iso-PGF2α浓度明显下降,而SOD浓度升高,差异均有统计学意义(P <0.05,P <0.01)。2组比较,研究组Ox-LDL及8-iso-PGF2α更低,SOD更高,差异均有统计学意义(P <0.01,P <0.05)。2组在研究期间均无出现任何不良反应。结论:参麦注射液联用瑞舒伐他汀钙治疗AIS疗效确切,具有调脂、抗氧化应激和抗脂质过氧化作用,有助于患者神经功能恢复,可对改善急性缺血性脑卒中患者临床预后起到积极的作用。

Objective： To observe the effect of Shenmai injection combined with rosuvastatin calcium on oxidative stress and lipid peroxidation in patients with acute ischemic stroke（AIS）. Methods： Divided 80 cases of AIS patients into two groups according to the random number table method, 40 cases in each group. The two groups were given AIS routine treatment. The control group was additionally given rosuvastatin calcium for treatment; the study group was additionally treated with rosuvastatin calcium combined with Shenmai injection. The two groups were treated for at least 3 weeks. Before and after treatment, scored the national institutes of health stroke scale （NIHSS） and detected the levels of oxidized low density lipoprotein（Ox-LDL）, superoxide dismutase（SOD）, serum triglyceride（TG）, total cholesterol（TC）, low density lipoprotein- cholesterol（LDL-C）, high density lipoprotein-cholesterol（HDL-C）, and 8-iso-Prostaglandin F2α（8-iso-PGF2α）in lipid peroxides. Evaluated the clinical effect and safety in the two groups. Results： The total effective rate in the study group was higher than that in the control group, there being no significance in the difference（P 〉0.05）. After treatment, the NIHSS scores in the two groups were decreased obviously when compared with those before treatment, and that in the study group was lower than that in the control group, differences being significant（P〈 0.05, P〈 0.01）. The levels of TG, TC and LDL-C in the two groups were decreased obviously when compared with those before treatment, while levels of HDL-C in the two groups were increased obviously when compared with those before treatment, differences being significant（P〈 0.01）. The above indexes in the study group were changed more obviously than those in the control group, differences being significant（P 〈0.05, P 〈 0.01）. After treatment, the level of Qx-LDL in the control group was increased when compared with that before treatment, while levels of SOD and 8-iso-PGF2α were decreased when compared with those before treatment, there was significant difference in the level of 8-iso-PGF2α（P〈0.01）. Levels of Ox-LDL and 8-iso-PGF2α in the study group were decreased obviously when compared with those before treatment, while the level of SOD was increased when compared with that before treatment, there was significant difference in the level of Ox-LDL and 8-iso-PGF2α（P〈 0.05, P〈 0.01）. Compared with those in the control group, levels of Ox-LDL and 8-iso-PGF2α in the study group were lower and the level of SOD was higher, differences being significant（P〈 0.01, P〈 0.05）. Neither group had any adverse reactions during the study. Conclusion. The therapy of Shenmai injection combined with rosuvastatin calcium has accurate therapeutic effect in treating AIS, has the functions of regulating lipid, anti-oxidative stress and anti-lipid peroxidation, which is helpful for the recovery of nerve function of patients and can play a positive role in improving the clinical prognosis of patients with AIS.